Suchergebnisse

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK

Current therapeutic options for the treatment of HIV provide high rates of virological suppression and good tolerability. However, as long‐term treatment success has become a realistic goal, data evaluating the long‐term efficacy and safety of switching strategies become more needed. The purpose of this sub‐analysis is to describe the long‐term outcomes of ATV/r regimens after switching from combinations containing non‐nucleoside reverse transcriptase inhibitor (NNRTI) in a clinical setting. Non‐comparative, retrospective study including data from 3 European databases (France – DatAids, Germany‐KompNet, Sweden‐InfCare). Data from antiretroviral (ARV)‐experienced adults starting an ATV/r‐regimen between October 2004‐March 2007 were extracted every 6‐months (maximum follow‐up 5 years). Time to virological failure (VF) was analysed by the Kaplan‐Meier method. Reasons for discontinuation and safety data were also collected. Of 1294 patients analysed, 250 switched from a NNRTI‐based regimen. Patients were predominantly male (74%); median age 42 years (min, max: 23, 85); prior ARV exposure: median 5.0 years. At baseline (BL), 56% of patients had HIV‐1 RNA<500 c/mL and 31% had<50 c/mL; median (min, max) CD4 cell count: 388 (6, 1299) cells/mm3. After 3‐year follow‐up, the probability of not having VF was 79% (95% CI 65–88%) and 62% (95% CI 52%–70%) for patients with BL HIV‐1 RNA<or≥50 c/mL, respectively. The most frequent reasons for discontinuation were "unknown" (18%) and adverse events (8%). Hyperbilirubinemia was reported as reason for discontinuation in only 2 patients. In a clinical setting, switching from NNRTI to ATV/r‐based regimen is associated with sustained virological suppression and good tolerability.Time to virological failure (2 consecutive HIV‐1 RNA≥50 c/mL or 1 HIIV‐1 RNA≥50 c/mL followed by discontinuation).image